CLAIMS

1. Use of hepcidin in the manufacture of a medicament for the treatment of a condition in a subject, said treatment comprising administering the medicament to the subject.

2. The use of claim 1, wherein administering the medicament to the subject comprises administering about 500 μg to about 10 mg of hepcidin.

3. The use of claim 2, wherein administering the medicament to the subject comprises administering about 1000 μg or about 5 mg of hepcidin.

4. The use of any one of claims 1 to 3, wherein administering the medicament comprises administering the composition at least once per week.

5. The use of claim 4, wherein administering the medicament comprises administering the composition 1, 2, or 3 times per week.

6. The use of claim 4 or 5, wherein about 500 μg to about 10 mg of hepcidin is to be administered each time the medicament is to be administered.

7. The use of claim 6, wherein about 1000 μg or about 5 mg of hepcidin is to be administered each time the medicament is to be administered.

8. The use of any one of claims 1 to 7, wherein the medicament is to be administered subcutaneously, intravenously, intramuscularly, intranasally, by inhalation, orally, sublingually, by buccal administration, topically, transdermally, or transmucosally.

9. The use of any one of claims 1 to 8, wherein the medicament is to be administered by injection.

10. The use of claim 8 or 9, wherein the medicament is to be administered subcutaneously.

11. The use of any one of claims 1 to 10, wherein the condition is α-thalassemia, thalassemia intermedia, β-thalassemia, hemochromatosis, or sickle cell disease.

12. The use of any one of claims 1 to 10, wherein the condition is anemia and the anemia is a hemoglobinopathy, sideroblastic anemia, refractory anemia, hemolytic anemia, anemia associated with myelodysplastic syndrome (MDS), or a congenital anemia.

13. The use of claim 12, wherein the condition is Diamond-Blackfan anemia.

14. The use of any one of the preceding claims, wherein the subject is a mammal.

15. The use of claim 14, wherein the subject is a human.

16. The use of any one of claims 1 to 15, wherein the medicament comprises hepcidin and the hepcidin comprises the amino acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

17. The use of any one of claims 1 to 15, wherein the medicament comprises hepcidin and the hepcidin comprises an amino acid sequence having at least 90% sequence homology with the amino acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

18. The use of claim 17, wherein the hepcidin comprises each of the 8 cysteines in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

19. The use of claim 16 or 18, wherein the 8 cysteines in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5 form 4 disulfide bonds in the hepcidin.

20. The use of any one of claims 16 to 19, wherein the hepcidin comprises the amino acid sequence set forth in SEQ ID NO:1.

21. The use of any one of claims 1 to 15, wherein the medicament comprises hepcidin and the hepcidin comprises the sequence set forth in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

22. The use of claim 21, wherein the 8 cysteines of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10 form 4 disulfide bonds in the hepcidin.